(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
How 2025 became the year of comet: The rise of interstellar 3I/ATLAS, an icy Lemmon and a cosmic SWAN - 2Finding Your Motivation: Moves toward a Satisfying Life
- 3Which Film Has the Incomparable Melodic Score?
- 4I'm 18 and founded an AI startup. I have to wake up at 3 a.m. to work on it before school, but it's worth every sleepless night.
- 5German Cabinet advances bill to cut greenhouse emissions from fuels
- What Yogurt Types Do You Know
- Language Learning Applications for Voyagers
- Watching ‘Home Alone’ with the kids this holiday season? Brace yourself for '6-7.'
- Day to day Temporary Positions That Compensate Fairly in the US
- Vote In favor of Your #1 sort of film
- Top Breakfast Food: What's Your Morning Enjoyment?
- Vote in favor of the subject that you see as generally captivating and intelligent!
- Medtronic has 'significant firepower' for multiple acquisitions, executives say
- Jason Kelce opens about wife Kylie Kelce's past pregnancy loss
